STRYKER CORP (SYK) Stock Analysis
STRYKER CORP (SYK) Stock Analysis
Analysis from 10-Q filed 2025-10-31. Data as of Q4 2025.
Overall Grade: F (Concerning)
STRYKER CORP faces challenges in financial performance that warrant careful analysis.
| Metric | Value | Context |
|---|---|---|
| ROIC | 10.1% | Near cost of capital |
| FCF Margin | 17.1% | Strong cash generation |
Investment Thesis: Healthy free cash flow margin of 17.1% provides financial flexibility for growth and shareholder returns.
Explore STRYKER CORP: Earnings History | Filing Intelligence | ROIC Analysis
Profitability: STRYKER CORP earns 10.1% ROIC, Top 50% in Healthcare
STRYKER CORP's trailing-twelve-month ROIC of 10.1% ranks Top 50% in Healthcare companies (sector median: -3.9%), driven by NOPAT margin of 14.0% combined with asset turnover of 0.5x. Source: 10-Q filed 2025-10-31. Gross margin of 64.0% with operating margin at 19.5% reflects strong pricing power.
| Metric | SYK | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.1% | Adequate | Above sector median of -3.9% |
| Gross Margin | 64.0% | Excellent | Strong pricing power |
| Operating Margin | 19.5% | Good | Efficient operations |
Cash Flow: STRYKER CORP generates $4.3B FCF at 17.1% margin, positive NaN/8 quarters
STRYKER CORP generated $4.3B in free cash flow (TTM), a 17.1% FCF margin, a margin that ranks Top 5% in Healthcare. Operating cash flow exceeds net income by 1.6x, indicating high earnings quality. FCF was positive in N/A of the last 8 quarters. Source: 10-Q filed 2025-10-31.
| Metric | SYK | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 17.1% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $4.3B | Good | Positive cash generation |
| OCF/Net Income | 1.6x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet Analysis for STRYKER CORP
Total debt of $15.9B offset by $4.1B in cash. Source: 10-Q filed 2025-10-31.
| Metric | SYK | Rating | Context |
|---|---|---|---|
| Net Cash Position | $-11.8B | Warning | Net debt position |
Valuation: STRYKER CORP trades at 41.4x earnings
STRYKER CORP trades at a P/E of 41.4x. Free cash flow yield of 3.2% reflects market expectations for growth.
| Metric | SYK | Rating | Context |
|---|---|---|---|
| P/E Ratio | 41.4x | Adequate | Premium valuation |
| EV/Sales | 5.9x | Adequate | Growth premium priced in |
| FCF Yield | 3.2% | Adequate | Lower cash yield |
| Dividend Yield | 1.0% | Adequate | Growth focus over income |
Capital Allocation: STRYKER CORP returns 1.0% shareholder yield
STRYKER CORP's total shareholder yield is 1.0% (dividends 1.0% + buybacks). Source: 10-Q filed 2025-10-31.
| Metric | SYK | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 1.0% | Adequate | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $1.3B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.1% | Top 50% | - |
| Free Cash Flow Margin | 17.1% | Top 5% | - |
| Gross Margin | 64.0% | Top 50% | 1.0x at |
| Operating Margin | 19.5% | Top 25% | 10.1x above |
| P/E Ratio | 41.4x | N/A | - |
Financial Scorecard
| Metric | SYK | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.1% | Adequate | Top 50% of sector (median: -3.9%) |
| Free Cash Flow Margin | 17.1% | Good | Top 5% of sector (median: 0.0%) |
| Gross Margin | 64.0% | Excellent | Top 50% of sector (median: 64.0%) |
| P/E Ratio (Price-to-Earnings) | 41.4x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 3.2% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is STRYKER CORP's Return on Invested Capital (ROIC)?
STRYKER CORP (SYK) has a trailing twelve-month Return on Invested Capital (ROIC) of 10.1%. This compares above the sector median of -3.9%. An ROIC near 8-12% is approximately the cost of capital for most companies.
Q: What is STRYKER CORP's Free Cash Flow Margin?
STRYKER CORP (SYK) has a free cash flow margin of 17.1%, generating $4.3 billion in free cash flow over the trailing twelve months. A FCF margin between 10-20% represents healthy cash generation for most industries.
Q: Is STRYKER CORP stock overvalued or undervalued?
STRYKER CORP (SYK) trades at a P/E ratio of 41.4x, which is above the sector median of N/A. The EV/Sales multiple is 5.9x. Free cash flow yield is 3.2%, which is in line with market averages.
Q: Does STRYKER CORP pay a dividend?
STRYKER CORP (SYK) currently pays a dividend yield of 1.0%. Including share buybacks, the total shareholder yield is 1.0%. The relatively low yield suggests the company prioritizes growth reinvestment over income distribution.
Q: What is STRYKER CORP's revenue and earnings growth?
STRYKER CORP (SYK) grew revenue by 11.2% year-over-year. Earnings per share increased by 8.2% compared to the prior year. Solid growth above 10% suggests healthy business momentum.
Q: How does STRYKER CORP compare to competitors in Healthcare?
Compared to other companies in Healthcare, STRYKER CORP (SYK) shows: ROIC of 10.1% is above the sector median of -3.9% (Top 26%). FCF margin of 17.1% exceeds the sector median of 0.0% (Top 0% of sector). Gross margin at 64.0% is 0 percentage points lower than sector peers. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with STRYKER CORP?
STRYKER CORP (SYK) shows no major financial warning signs based on current metrics. However, investors should always monitor: 1) Margin compression trends, 2) Cash flow consistency, 3) Debt levels relative to cash generation, and 4) Changes in competitive positioning.
Data Source: Data sourced from 10-Q filed 2025-10-31. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.